# IMGT

Source: https://onco.cc/companies/imgt/  
OnCo record `imgt` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IMGT is a South Korean company whose device aims focused ultrasound at a tumour during chemotherapy, to help the drugs get into the cancer. It is starting a large trial in pancreatic cancer that cannot yet be removed by surgery.

## Summary

IMGT Co., Ltd. (아이엠지티) is a medical device company in Seongnam, South Korea, established in April 2010, according to the company. Its 'chemosono therapy' uses non-thermal, non-destructive focused ultrasound to produce cavitation that temporarily opens tumour blood vessels and cell membranes, with the aim of increasing penetration of chemotherapy into the tumour. The IMD10 system, for pancreatic cancer, began a Korean clinical trial in 2023 after an investigational device exemption from Korea's MFDS in 2022, with interim results released in April 2025; the FDA approved an investigational device exemption for IMD10 in November 2025. A second system, IMD20, received an MFDS investigational device exemption in 2023. The company listed on Korea's KONEX market in July 2023 and reports Series A to D financings, the latest in April 2025, without amounts on its website. Its first registered cancer trial, NCT07325214, a randomised, multiregional pivotal study of IMD10 with FOLFIRINOX-type chemotherapy against chemotherapy alone, with overall survival as the measure, in borderline resectable or locally advanced pancreatic cancer at US and Korean sites, was posted on ClinicalTrials.gov in January 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: IMGT Co., Ltd.; 아이엠지티
- HQ: Seongnam
- Type: devices
- Website: http://www.nanoimgt.com/

## Notes

- The KONEX ticker code was not read, so no ticker is recorded.
- The company history lists a breakthrough device designation in February 2025 without naming the agency, and a Korean innovative medical device designation in January 2026.
- A March 2026 disclosure notes a change of registered head office; the website still gives the Seongnam address.
- Financing amounts are not given on the company website; the history mentions government project awards of $17 million (2023) and $5 million (2020) as stated by the company.
- Company website read on 29 October 2026.

## Sources

- Official website: http://www.nanoimgt.com/
- Company history: http://www.nanoimgt.com/s1/s1_3.php
- ClinicalTrials.gov: pivotal trial of IMD10 focused ultrasound with chemotherapy in pancreatic cancer (NCT07325214): https://clinicaltrials.gov/study/NCT07325214

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Devices & Physical Therapies](https://onco.cc/fronts/devices/)
- technologies: [Focused ultrasound & histotripsy](https://onco.cc/technologies/hifu-histotripsy/), [Ultrasound](https://onco.cc/technologies/ultrasound/)

---
JSON: https://onco.cc/api/v1/entities/imgt.json